Molecular and Cellular Biochemistry, Год журнала: 2025, Номер unknown
Опубликована: Апрель 24, 2025
Язык: Английский
npj Vaccines, Год журнала: 2025, Номер 10(1)
Опубликована: Фев. 7, 2025
The pivotal role of type 1 conventional dendritic cells (cDC1s) in the field cell (DC)-based tumor immunotherapies has been gaining increasing recognition due to their superior antigen cross-presentation abilities and essential modulating immune responses. This review specifically highlights C-type lectin receptor family 9 member A (Clec9a or DNGR-1), which is exclusively expressed on cDC1s plays a augmenting cytotoxic T lymphocyte (CTL) responses while simultaneously mitigating off-target effects. These effects include enhancement cross-presentation, reducing autoimmune systemic inflammation, as well preventing non-specific activation other cells. Consequently, these actions may contribute reduced toxicity enhanced treatment efficacy immunotherapy. exceptional ability Clec9a cross-present dead cell-associated antigens enhance both humoral CTL makes it an optimal for DC-based strategies aimed at strengthening antitumor immunity. provides comprehensive overview molecular characterization, expression, signaling mechanisms Clec9a. Furthermore, discusses induction functional Clec9a+ cDC1s, with particular focus addressing challenges related tolerance development vaccines. Additionally, this explores potential Clec9a-targeted approaches immunogenicity vaccines addresses utilization delivery target specific agonists (such STING αGC) therapeutic novel approach leverages Clec9a's capacity improve precision immunomodulatory molecules treatment. In summary, presents compelling evidence positioning promising immunotherapy, capable enhancing minimizing adverse
Язык: Английский
Процитировано
0
Molecules, Год журнала: 2025, Номер 30(6), С. 1257 - 1257
Опубликована: Март 11, 2025
The use of nanoparticles as drug carriers in oncology has evolved from their traditional role chemotherapy to application immunotherapy, exploiting not only passive accumulation solid tumors but also ability interact with immune cells. Silicasomes are highly versatile nanoplatforms composed a mesoporous silica core whose external surface is coated lipid bilayer that allows the co-delivery therapeutic agents having different chemical natures (small molecules, proteins, enzymes, or oligonucleotides, among others). Herein, cutting-edge advances carried out development and silicasomes presented, providing general description performance these nanotransporters. Additionally, specific load chemotherapeutic drugs explored, followed by discussion immunotherapeutic combination strategies, including theragnosis, single silicasome platform, highlighting enormous potential nanosystems.
Язык: Английский
Процитировано
0
Essays in Biochemistry, Год журнала: 2025, Номер 69(02)
Опубликована: Март 28, 2025
The emergence of immunotherapy has led to the clinical approval several related drugs. However, their efficacy against solid tumors remains limited. As hub immune activation, lymph nodes (LNs) play a critical role in tumor by initiating and amplifying responses. Nevertheless, intricate physiological structure barriers within LNs, combined with immunosuppressive microenvironment induced cells, significantly impede therapeutic immunotherapy. Engineered nanoparticles (NPs) have shown great potential overcoming these challenges facilitating targeted drug transport LNs directly or indirectly activating T cells. This review systematically examines structural features key factors influencing targeting efficiency NPs, current strategies for remodeling LNs. Additionally, it discusses future opportunities optimizing NPs enhance immunotherapy, addressing translation safety evaluation.
Язык: Английский
Процитировано
0
Asian Journal of Surgery, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Cell Communication and Signaling, Год журнала: 2025, Номер 23(1)
Опубликована: Апрель 7, 2025
The cGAS-STING signaling pathway serves as a critical link between DNA sensing and innate immunity, has tremendous potential to improve anti-tumor immunity by generating type I interferons. However, STING agonists have shown decreasing biotherapeutic efficacy in clinical trials. Tumor metabolism, characterized aberrant nutrient utilization energy production, is fundamental hallmark of tumorigenesis. And modulating metabolic pathways tumor cells been discovered therapeutic strategy for tumors. As research concerning progressed, emerging evidence highlights its role reprogramming, independent immune function, indicating targets activation cancers. In this review, we delve into the interplay multiple pathways. We also synthesize current knowledge on antitumor functions STING, within microenvironment (TME) that could be exploited activation. This review necessity future dissect complex interactions with various cancer types, emphasizing personalized strategies based profiling.
Язык: Английский
Процитировано
0
Nano Letters, Год журнала: 2025, Номер unknown
Опубликована: Апрель 22, 2025
Activation of the stimulator interferon genes (STING) pathway holds immense potential for cancer immunotherapy. However, clinical translation STING agonists such as cyclic GMP-AMP (cGAMP) is hindered by their inherent instability and poor cellular uptake efficacy. Herein, we report an iron oxide nanoparticle (IONP)-based carrier delivering cGAMP via coordination chemistry. The ribose, phosphate, adenine on were leveraged to directly bind IONP, resulting in cGAMP-functionalized IONPs (Fe-cGAMP). Such a design greatly improved activation efficacy cGAMP. Beyond delivery, promoted reactive oxygen species (ROS) production activated Toll-like receptors, leading synergistic immune alongside Fe-cGAMP exhibited robust antitumor effects multiple mouse tumor models. In combination with checkpoint inhibitors, could induce complete remission over 50% treated mice, these mice also remain tumor-free upon subsequent challenge, demonstrating strong long-lasting responses.
Язык: Английский
Процитировано
0
Molecular and Cellular Biochemistry, Год журнала: 2025, Номер unknown
Опубликована: Апрель 24, 2025
Язык: Английский
Процитировано
0